Genetherapy for Head and Neck Cancer using carrier cell-based delivery of replication-selective adenoviral vector

点击翻译按钮获取中文摘要

While multimodal treatments have been performed for the treatment of head and neck cancers, the prognoses of the patients with advanced head and neck cancer are still poor. The estimated survival rates of those patients are around 30%. New strategies for the treatment for head and neck cancer are desirable. To address this issue, we developed the midkine promoter-driven replication-selective adenoviral vector containing siRNA for EGFR or VEGF. With this adenoviral vector, synergistic effect of oncolytic adenovirus and inhibition of oncogene via RNA interference is effect.